Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.70 |
| ▸ | CA2 | P00918 | 2/20 | 0.70 |
| ▸ | CA12 | O43570 | 1/20 | 0.70 |
| ▸ | TYR | P14679 | 1/20 | 0.70 |
| ▸ | CA7 | P43166 | 1/20 | 0.70 |
| ▸ | CA9 | Q16790 | 1/20 | 0.70 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.70 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.60 |
| ▸ | TTR | P02766 | 1/20 | 0.59 |
| ▸ | APP | P05067 | 1/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | JAK2 | O60674 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | FDPS | P14324 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1233254 | 1.00 | CA1 (0.70) | CA1CA2CA12TYRCA7 | |
| Hydrochloric Acid SCHEMBL7439394 | 0.98 | CA1 (0.68) | CA1CA2CA12TYRCA7 | |
| Hydrochloric Acid SCHEMBL3552479 | 0.98 | CA1 (0.68) | CA1CA2CA12TYRCA7 | |
| SCHEMBL17457052 | 0.92 | CA1 (0.60) | CA1CA2CA12TYRCA7 | |
| SCHEMBL17457050 | 0.92 | CA1 (0.60) | CA1CA2CA12TYRCA7 | |
| SCHEMBL28852448 | 0.92 | CA1 (0.60) | CA1CA2CA12TYRCA7 | |
| SCHEMBL71224 | 0.90 | CA12 (0.84) | CA1CA2CA12TYRCA7 | |
| SCHEMBL5057418 | 0.90 | CA12 (0.84) | CA1CA2CA12TYRCA7 | |
| Hydrochloric Acid SCHEMBL27534488 | 0.87 | CA12 (0.55) | CA1CA2CA12TYRCA7 | |
| SCHEMBL18410060 | 0.85 | MAPT (0.71) | CA1CA2CA12TYRCA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118724825-A | Mer/HDAC double-target inhibitor and application thereof in preparation of antitumor drugs | 河北科技大学 | 2024-10-01 | — | — | CN | claimed |
| CN-101774918-A | Preparation method of cinnamate derivates | UNIV HUAQIAO | 2010-07-14 | — | — | CN | claimed |
| EP-0713859-B1 | Cinnamic acid derivatives, photocrosslinkable cinnamic acid-polymer derivative and crosslinked cinnamic acid polymer derivatives | SEIKAGAKU KOGYO CO LTD (JP) | 2000-08-30 | — | — | EP | claimed |
| CN-122095297-A | Composition for forming cured film, alignment material, and phase difference material | — | 2026-05-26 | — | — | CN | disclosed |
| EP-4719602-A1 | ANTI-HIV COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-04-08 | — | — | EP | disclosed |
| WO-2025088969-A1 | COMPOSITION FOR FORMING CURED FILM, CURED FILM, ALIGNMENT MATERIAL, AND RETARDATION MATERIAL | 日産化学株式会社 | 2025-05-01 | — | — | WO | disclosed |
| US-20250051375-A1 | ANTI-HIV COMPOUNDS | GILEAD SCIENCES, INC. | 2025-02-13 | — | — | US | disclosed |
| WO-2025023309-A1 | COMPOSITION FOR FORMING CURED FILM, ALIGNMENT MATERIAL, AND PHASE-DIFFERENCE MATERIAL | 日産化学株式会社 | 2025-01-30 | — | — | WO | disclosed |
| WO-2025011632-A1 | HYDROXIMIC ACID COMPOUNDS CONTAINING TETRAHYDROBENZO[4,5]FURANO[2,3-C]PYRIDINE, PREPARATION METHOD THEREFOR, AND USES THEREOF | 浙江大学 | 2025-01-16 | — | — | WO | disclosed |
| WO-2024249517-A1 | ANTI-HIV COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| CN-113874470-B | Composition for forming cured film, alignment member, and phase difference member | 日产化学株式会社 | 2024-11-19 | — | — | CN | disclosed |
| EP-0642508-A1 | TRICYCLIC QUINOXALINEDIONES AS GLUTAMATE RECEPTOR ANTAGONISTS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1995-03-15 | — | — | EP | disclosed |
| US-5360819-A | Nonradioactive labels which provide a ketone signal, vapor phase analysis | NORTHEASTERN UNIVERSITY (US) | 1994-11-01 | — | — | US | disclosed |
| WO-1993008188-A1 | TRICYCLIC QUINOXALINEDIONES AS GLUTAMATE RECEPTOR ANTAGONISTS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1993-04-29 | — | — | WO | disclosed |
| US-5096919-A | Pyrrolylphenyl-substituted hydroxamic acid derivatives | CIBA-GEIGY CORPORATION (US) | 1992-03-17 | — | — | US | disclosed |
| EP-0378991-A1 | Certain pyrrolylphenyl-substituted hydroxamic acid derivatives | CIBA-GEIGY AG (CH) | 1990-07-25 | — | — | EP | disclosed |
| US-4388459-A | HYPOLIPIDEMIC, ANTIATHEROSCLEROTIC | AMERICAN CYANAMID COMPANY (US) | 1983-06-14 | — | — | US | disclosed |
| US-4379819-A | OIL SOLUBLE MONOAZO DYE | CIBA-GEIGY AG (CH) | 1983-04-12 | — | — | US | disclosed |
| US-4259352-A | 4-[Cycloalkyl- or cycloalkenyl-amino(cycloalkyl- or cycloalkenyl-alkenyl)amino]phenyl compounds, useful as hypolipidemic and antiatherosclerotic agents | AMERICAN CYANAMID COMPANY (US) | 1981-03-31 | — | — | US | disclosed |
| US-4094636-A | DIAZOTIZATION | HOECHST AKTIENGESELLSCHAFT (DT) | 1978-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051375-A1 | ANTI-HIV COMPOUNDS | CCR5, CD4, NFATC1 | CA1 4857/4885CA2 4208/4885CA12 4488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.